INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,575,742 | -18.0% | 87,843 | -0.4% | 0.39% | -16.5% |
| Q2 2023 | $5,583,368 | +13.2% | 88,177 | -3.2% | 0.47% | +8.8% |
| Q1 2023 | $4,932,849 | +1.1% | 91,096 | -1.2% | 0.43% | -3.2% |
| Q4 2022 | $4,877,689 | -5.0% | 92,171 | +2.4% | 0.44% | -32.7% |
| Q3 2022 | $5,137,000 | +0.2% | 89,994 | +0.2% | 0.66% | +35.8% |
| Q2 2022 | $5,128,000 | -7.5% | 89,844 | -0.8% | 0.49% | -22.5% |
| Q1 2022 | $5,542,000 | +18.9% | 90,544 | +1.7% | 0.63% | +15.9% |
| Q4 2021 | $4,661,000 | – | 89,051 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |